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Urinary microRNAs as non‑invasive 
biomarkers for toxic acute kidney 
injury in humans
Fathima Shihana1,2,3*, Wilson K. M. Wong4, Mugdha V. Joglekar4, Fahim Mohamed1,2,5,6, 
Indika B. Gawarammana2, Geoffrey K. Isbister7, Anandwardhan A. Hardikar4,8,11, 
Devanshi Seth3,9,10,11 & Nicholas A. Buckley1,2,10,11*
MicroRNAs in biofluids are potential biomarkers for detecting kidney and other organ injuries. We 
profiled microRNAs in urine samples from patients with Russell’s viper envenoming or acute self‑
poisoning following paraquat, glyphosate, or oxalic acid [with and without acute kidney injury (AKI)] 
and on healthy controls. Discovery analysis profiled for 754 microRNAs using TaqMan OpenArray 
qPCR with three patients per group (12 samples in each toxic agent). From these, 53 microRNAs were 
selected and validated in a larger cohort of patients (Russell’s viper envenoming = 53, paraquat = 51, 
glyphosate = 51, oxalic acid = 40) and 27 healthy controls. Urinary microRNAs had significantly higher 
expression in patients poisoned/envenomed by different nephrotoxic agents in both discovery and 
validation cohorts. Seven microRNAs discriminated severe AKI patients from no AKI for all four 
nephrotoxic agents. Four microRNAs (miR‑30a‑3p, miR‑30a‑5p, miR‑92a, and miR‑204) had > 17 fold 
change (p < 0.0001) and receiver operator characteristics area‑under‑curve (ROC‑AUC) > 0.72. Pathway 
analysis of target mRNAs of these differentially expressed microRNAs showed association with the 
regulation of different nephrotoxic signaling pathways. In conclusion, human urinary microRNAs 
could identify toxic AKI early after acute injury. These urinary microRNAs have potential clinical 
application as early non‑invasive diagnostic AKI biomarkers.
Main
MicroRNAs are involved in all cellular functions, including development, differentiation, growth, metabolism and 
regulate numerous physiological and pathophysiological  processes1,2. MicroRNAs are endogenous, non-coding 
RNAs, 21–25 nucleotides in size that regulate gene expression by binding to target messenger RNAs (mRNAs). 
Cells secrete microRNAs into the extracellular environment to function as regulators, carrying genetic informa-
tion from one cell to another, or following cell  injury3. These extracellular microRNAs are potential biomarkers 
for a variety of diseases including acute kidney injury (AKI)4 and can also be mediators of disease.
Acute kidney injury is associated with changes in the expression of specific microRNAs. While some micro-
RNAs contribute to the pathogenesis and progression of AKI, others may serve as protective  molecules5. As 
signalling molecules, microRNAs mediate cell–cell communications, and form a complex regulatory  network2,6. 
They play a critical role as anti-apoptotic, pro-apoptotic and inflammatory molecules to facilitate the development 
of renal injury in nephrotoxic  AKI7,8. Thus, microRNAs have not only emerged as novel biomarkers for AKI, 
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but they also hold promise as potential therapeutic targets.Various microRNAs regulate different nephrotoxic 
pathways, for example NF-κB dependent inflammatory responses, TGF-β signalling, and oxidative  stress9–11. 
Thus, different mechanisms of nephrotoxicity including renal tubular toxicity, inflammation, glomerular damage, 
crystal nephropathy, and thrombotic microangiopathy from different toxic agents would be expected to lead to 
variable microRNA expression.
Traditional biomarkers of AKI such as serum creatinine (SCr) or urine output are both late indicators of 
kidney  injury12,13. Further, the rapid rise of SCr after oxalic acid, paraquat, and glyphosate surfactant herbi-
cide (glyphosate) poisoning suggests other mechanisms occur beyond loss of renal  function14–16. Protein bio-
markers which reflect the underlying renal glomerular and/or tubular damage during nephrotoxicity such as 
β2-microglobulin, cystatin C (Cys C), albumin, neutrophil gelatinase-associated lipocalin (NGAL), kidney 
injury molecule-1 (KIM-1), interleukin-18 (IL-18) have highly variable diagnostic performance in these three 
 poisonings14–16. New biomarkers that are consistent for early prediction and/or detection of diverse causes of 
nephrotoxic AKI are needed, whilst those specific to particular toxins may provide further understanding of 
the mechanisms of nephrotoxicity.
Acute kidney injury is a common clinical complication following envenoming and  poisoning14,16–18. Our 
main aim was to explore if urinary microRNAs can be used as early renal biomarkers following nephrotoxic-AKI 
(snakebite envenoming, oxalic acid, paraquat, and glyphosate poisoning). We also investigated whether micro-
RNA signatures identify some common mechanisms of nephrotoxicity using target mRNAs and pathway analysis.
Results
Global profiling of urinary microRNAs detects AKI after different causes of poisoning. We 
identified 112 differentially expressed urinary microRNAs from the discovery cohort of 48 patients with Rus-
sell’s viper envenoming or acute self-poisoning following  paraquat, glyphosate or oxalic acid. The cohort 
included those who developed no injury (NOAKI), mild injury (AKIN1), moderate injury (AKIN2) or severe 
injury (AKIN3) (n = 3 per group and n = 12 per each toxins) as well as healthy controls (n = 3). The expression 
of microRNAs was significantly upregulated in urine samples of patients who developed moderate to severe 
injury (AKIN2/3) compared to the NOAKI and healthy controls in the discovery cohort. Supervised hierarchi-
cal clustering heat map demonstrates the differentially expressed microRNAs between patients with moderate to 
severe AKI (AKIN2/3) from NOAKI and healthy controls (Fig. 1). Based on our discovery analysis or from past 
literature, we selected a set of 53 microRNAs (> 4 fold change and p < 0.01; Supplementary Table 1) for further 
validation in independent cohorts for each toxins (Russell’s viper bite = 53, paraquat = 51, glyphosate = 51, oxalic 
acid = 40, and 27 healthy controls) (see “Methods” section and Supplementary Table 2 for details).
Clustering of microRNA in severe cases from different causes of AKI in the validation 
cohort. Forty four microRNAs were significantly upregulated in AKI in one or more nephrotoxic agents 
(oxalic acid = 25, glyphosate = 10, paraquat = 34 and Russell’s viper = 25) compared to NOAKI. Thirty two micro-
RNAs were upregulated for two or more agents (Supplementary Table 3). Different sets of microRNAs for dif-
ferent toxins distinguished patients with AKI from NOAKI in the validation cohort (Fig. 2). Twelve microRNAs 
distinguished AKI from NOAKI for only one specific toxin [oxalic acid (n = 2), paraquat poisoning (n = 5), Rus-
sell’s viper envenoming (n = 5)] (Supplementary Table 3).
Urinary microRNAs provide signals distinguishing both kidney injury severity and toxic 
agents. Differentially expressed microRNAs from all four nephrotoxic agents were examined together to 
visualize separation of patients with AKI from NOAKI using tSNE clustering analysis (Fig. 3a). Despite the 
selection of differentially expressed microRNAs based on comparisons across all causes of kidney injury for 
validation, there was still apparent glyphosate clustering in the tSNE plot (Fig. 3b). Seven common microRNAs 
discriminated AKIN2/3 patients from NOAKI for all four nephrotoxic agents (Fig. 3c, Supplementary Table 3). 
Of these seven microRNAs, four (miR-30a-5p, miR-30b, miR-191, and miR-204, Fig. 3d) had a greater than 
17-fold change (p < 0.0001) and ROC-AUC = 0.72 (Table  1). Logistic regression combination of four and all 
seven microRNAs in NOAKI versus AKIN2/3 patients showed AUC-ROC values of 0.75 and 0.77 respectively 
(Supplementary Figure 1). The four microRNAs showed an association with increasing disease severity in all 
poisoning (Jonckheere–Terpstra nonparametric ordered test, p < 0.0001, Fig.  4). A schematic diagram shows 
the initial discovery, through validation and selection of four common microRNAs in all four toxic agents (Sup-
plementary Figure 2).  
Identification of target genes and pathway analysis. The seven most differentially expressed micro-
RNAs target glomerular injury, renal cell death/necrosis, renal inflammation and renal nephritis as major dis-
ease/functions (Fig. 5a). For the seven differentially expressed microRNAs a total of 586 potential target mRNAs 
specific to kidney disease/functions were identified via Ingenuity Pathway Analysis (data not shown). These 
differentially expressed microRNAs targeted many genes associated with the regulation of different nephrotoxic 
signalling pathways (Fig. 5b). The key pathways targeted by these microRNAs were oxidative stress, renal cell 
death/necrosis, oxidative stress, apoptosis and mitochondrial dysfunction (Fig. 5b).
Discussion
We report urinary microRNA signatures for nephrotoxicity in patients with four very different toxic agents 
(snake envenoming, pesticide and chemical poisoning) in humans. We identified seven common microRNAs 
that correlated with kidney injury across all four nephrotoxic agents. Another 36 microRNAs provided signals 
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for certain nephrotoxic causes, but not for all agents. We found many of the target mRNAs of these seven com-
mon microRNAs are involved in cellular pathways that promote inflammation, apoptosis and oxidative stress.
Very few studies report on multiple agents in nephrotoxic AKI. A recent report on drug induced-AKI in 
rats using three very different nephrotoxic compounds, cisplatin (proximal tubule) puromycin (glomerulus) 
and N-phenylanthranylic acid (collecting ducts), identified microRNAs specific to each agent, but did not find 
any commonly expressed microRNAs across all  three19. Other studies reported on single agents, for example, 
cisplatin-induced AKI in rats showed higher expression of urinary miR-191 and miR-30a-5p20, and urinary levels 
of miR-423 were significantly higher in both paracetamol overdose patients with AKI compared with healthy 
controls and in paracetamol overdose patients without  AKI21.
We also noted some urinary microRNAs we identified are also observed in non-toxic AKI and other kidney 
diseases as AKI biomarkers. Urinary miR-423 expression increased in critically ill patients (intensive care unit-
AKI)22. Patients with glomerular disease such as idiopathic nephrotic syndrome and focal segmental glomerulo-
sclerosis had high levels of miR-30a-5p in urine compared to  controls23–25. MiR-204 was differentially expressed 
in urine of patients with chronic acute cellular rejection, characterized by interstitial fibrosis and tubular atrophy, 
compared with patients with normal histology and functioning  allografts26.
We studied four very different toxins covering a broad range of mechanisms including ischemia–reperfusion 
(Russell’s viper bite), uncoupling of oxidative phosphorylation (glyphosate), free radical generation (paraquat), 
Figure 1.  Urinary microRNAs detect AKI after different causes of poisoning. Supervised hierarchical 
clustering heat map of differentially expressed microRNAs (n=112) distinguished patients with severe AKI 
from NOAKI and healthy controls. Green, cyan, maroon, dark blue and purple indicates healthy controls, 
paraquat, Glyphosate, Oxalic acid and Russell’s viper bite respectively. AKI stages are numbered as 0, 1, 2 and 3 
for NOAKI, AKIN1, AKIN2 and AKIN3 respectivly. Rows represent microRNAs (normalised Ct) and columns 
represent the individual samples from healthy controls and patients.
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and crystal formation (oxalic acid). However, all these poisonings or envenoming cause mitochondrial damage 
Figure 2.  tSNE plots show the clusters of individual microRNAs with NOAKI, AKIN1, AKIN2 and AKIN3 
caused by different poisons. Left panels show plots of the non-linear tSNE map of samples in validation cohort 
using each specific set of differentially expressed microRNAs for different poisons (oxalic acid, glyphosate, 
paraquat) and Russell’s viper bite, (Supplementary Table 3). Plots were generated using 4-dimensional principal 
component space into two dimensions showing tSNE analysis. Each point represents a single sample. The right 
panel shows the expression of the top four most significantly altered microRNAs for each poison presented as 
individual tSNE-projections. Blue to red presented in the color bar indicate high to low microRNA expression 
(data shown in normalized Ct values, therefore a lower value represents a higher expression) respectively.
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and inflammation triggering oxidative  stress27. Oxidative stress, both directly and indirectly affects all facets of 
the kidney, including vascular reactivity and renal hemodynamics, glomerular filtration and tubular reabsorption 
and secretion in all nephron  segments28. During poisoning, oxidative stress signalling alters all these processes 
and promotes damage pathways that lead to cellular apoptosis, necrosis, altered gene expression, progression of 
tissue damage, promotion of fibrosis and abnormal kidney  function27,28. We identified several target mRNAs of 
Figure 3.  Plot of the non-linear tSNE map of samples from 4-dimensional principal component space into two 
dimensions showing tSNE analysis applied using all (n=43) differentially expressed microRNAs (Supplementary 
Table 3). (a) tSNE plots show the clusters of all different microRNAs in different AKI stages: NOAKI, AKIN1, 
AKIN2 and AKIN3 caused by all poisons. (b) tSNE plots show the clusters for different poisons: oxalic acid, 
glyphosate, paraquat and Russell’s viper envenoming in validation cohort. (c) Venn Diagram demonstrating 
overlap of 43 altered microRNAs in AKI (> 2.8 fold change, p < 0.05) amongst the nephrotoxic agents. 
microRNAs altered in different agents: Oxalic acid = 25, glyphosate = 10, paraquat = 34 and Russell’s viper = 25. 
(d) tSNE plots show best four microRNAs clusters in AKIN2/3 patients in all four nephrotoxic agents. Blue to 
red presented in the color bar indicates high to low microRNA expression (data shown in normalized Ct values, 
therefore a lower value represents a higher expression) respectively.
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the altered microRNAs were associated with mitochondrial dysfunction, apoptosis, oxidative stress and necrosis/
cell death.
Most nephrotoxic agents induce proximal tubular injury. The increased concentration of microRNAs in 
urine may be due to leakage of microRNAs from proximal tubular cells with corresponding decreased levels of 
microRNAs in the injured  tissue20, but we did not test this due to unavailability of kidney tissue. Other studies 
in cisplatin and gentamicin-induced proximal tubular injury showed increased miR-191 and miR-30 family 
in urine with corresponding decreased expression in  tissue20,29,30. In human miR-30a-3p, miR-30b, miR-30c, 
miR-30e-3p had lower expression in acute kidney rejection biopsies compared to normal allograft  biopsies31.
Interestingly, there are no studies highlighting urinary miR-204 in AKI, despite its renal specific  expression32,33. 
MiR-204, that we found common across the four nephrotoxic agents, is involved in the regulation of epithelial-
mesenchymal transition by targeting specificity protein 1 (SP1) in the tubular epithelial cells after ischemia–reper-
fusion  injury34, and controls local inflammation by regulating interleukin-6 (IL-6) receptor  expression35. MiR-204 
protects interstitial tissue of renal tubules from chronic fibrotic  change34.
Table 1.  Diagnostic performance of the seven microRNAs in all causes of AKI (NOAKI vs. AKIN2/3). 
Diagnostic performance of the seven microRNAs that distinguished AKI in all poisoning was assessed using 
normalized Ct values. p values represent Mann–Whitney-U between NOAKI (n = 57) versus AKIN2/3 (n = 94).
miR Fold change  (2^ΔCt) p value AUC (95% CI)
miR-30a-5p 19.7 < 0.00001 0.72 (0.66–0.79)
miR-30b 17.1 < 0.00001 0.72 (0.66–0.79)
miR-191 32.0 < 0.00001 0.72 (0.66–0.78)
miR-204 17.1 < 0.00001 0.72 (0.65–0.78)
miR-30a-3p 22.6 < 0.00001 0.70 (0.64–0.77)
miR-660 8.0 < 0.00001 0.64 (0.59 0.69)
miR-423-5p 5.7 < 0.00001 0.60 (0.56–0.64)
Figure 4.  Top four microRNAs associated with AKI for all toxic agents. Violin plots show these microRNAs 
having increased abundance with increasing AKI severity in all four toxins. Blue lines indicate the medians 
and each black dot presents a different sample from validation cohort. The y-axis is relative abundance from 
the detectable limit  (2(39-Ct), Ct of 39 is the threshold of detectability). MicroRNA expressions were normalised 
using two spike control ath-microRNAs (ath-miR-159a and ath-miR-172a). p is the alternative p value from 
Jonckheere–Terpstra nonparametric ordered test.
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Figure 5.  Functions and nephrotoxic pathways associated with target mRNAs of seven differentially expressed 
microRNAs in toxic-AKI. We analyzed the expression of the seven microRNAs using co-analysis in Ingenuity 
Pathway Analysis (IPA), (QIAGEN, Inc., https:// targetexplorer.ingenuity.com/) and a) shows the main disease 
and functions of the differentially expressed microRNAs. We used IPA to identify target mRNA and microRNA-
mRNA interactions. Target mRNAs were overlaid on ‘Toxic’ functions derived from select microRNAs using 
‘Pathway design’ option in IPA. The top seven toxic function pathway (Tx) networks identified for microRNA-
mRNA interactions are presented here.
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One of our study limitations is that we had a relatively small sample size in the discovery cohort, but we vali-
dated the most differentially expressed microRNAs obtained from the discovery results in a much larger cohort. 
Furthermore, rather than only measuring previously studied microRNAs, we globally profiled 754 microRNAs 
without ‘a priori’ approach and hence successfully discovered novel microRNAs associated with nephrotoxic 
agents-induced AKI. We were unable to measure microRNA expression in kidney tissue as biopsies were not 
done on our patients limiting the study to some extent. As for most studies in patients, we did not have baseline 
serum creatinine measurement prior to injury and had to use the lowest level measured at any time which may 
underestimate the degree of injury.
The major strengths of this study are the comprehensive microRNA analysis of kidney injury with four differ-
ent toxins, global profiling of microRNAs and validation in independent sets of samples using the same analysis 
platform. Use of multi-centre prospective study samples from five different geographic regions of Sri Lanka is 
also a strength of the study for generalisability of results. Another strength of the study is that most patients’ 
samples were taken within 8 h of the injury, a timeframe important for clinical prediction of AKI and guiding 
treatment plans. Therefore, microRNAs identified in our study can readily serve as potential biomarkers for AKI.
In conclusion, urinary microRNA profiling shows promise in identifying nephrotoxicity after severe AKI in 
humans. Signature microRNAs including miR-30a-5p, miR-30b, miR-191 and miR-204, could be promising early 
biomarkers for the detection of toxic AKI. Urinary microRNAs have potential clinical applications as early non-
invasive biomarkers for AKI, toxic-AKI, and also for snake envenoming.
Methods
We included patients with Russell’s viper envenoming or who ingested oxalic acid, paraquat, or glyphosate from 
a multicenter cohort study in Sri  Lanka16,17,36. These patients presented to general hospitals between October 
2010 and February 2014. Participants completed a written informed consent prior to inclusion in this study. We 
included patients who provided admission urine samples (collected within 8 h of ingestion). Details of sample 
collection and storage are  described16,17,36. AKI was defined by serum creatinine (SCr) and categorized based on 
Acute Kidney Injury Network (AKIN)  criteria37. In brief, definition of AKIN stage 1 (mild): an absolute increase 
in SCr of more than or equal to 0.3 mg/dl or a relative increase by more than or equal to 150 to 200% (1.5 to 2 
fold) from baseline, AKIN stage 2 (moderate): a relative increase in SCr of > 200 to 300% (> 2 to 3 fold) from 
baseline and AKIN stage 3 (severe): a relative increase in SCr of > 300% (> 3 fold) from baseline (or an absolute 
increase of SCr by more than or equal to 4.0 mg/dl). We used baseline SCr as the lowest level measured at any 
time (hospital stay or follow-up) because information on pre-exposure was not available.
This study was approved by the Human Research Ethics Committees of the University of New South Wales 
(Sydney), Australia and the Faculty of Medicine, University of Peradeniya, Sri Lanka. We confirm that all methods 
were performed in accordance with the relevant guidelines and regulations.
Sample selection for global profiling and independent validation phase. We used urine samples 
from patients with acute self-poisoning following paraquat, oxalic acid and glyphosate, and patients who were 
envenomed by Russell’s vipers. We grouped patients into those who developed no kidney injury (NOAKI), mild 
injury (AKIN1) moderate injury (AKIN2) or severe injury (AKIN3) (n = 3 per group, n = 12 per each toxin) as 
well as healthy controls (n = 3) and profiled for microRNAs using the TaqMan OpenArray quantitative real-time 
PCR (qPCR) platform. We selected a panel of 53 microRNAs (46 significantly different microRNAs between 
AKI and NOAKI in all toxins in discovery cohort with fold change > 4.0, p < 0.01; seven from literature and two 
were stage-specific spike-in controls and one A. thaliana (ath-miR-394a) negative microRNA control) (Sup-
plementary Table 1). These were validated in a larger independent cohort of patients (Russell’s viper bite = 53, 
paraquat = 51, glyphosate = 51, oxalic acid = 40) and 27 healthy controls (Supplementary Table 2).
RNA extraction. Total RNA (including small RNA species) was extracted from 200 µl urine by first mixing 
with 500 µl of TRIzol (ThermoFisher Scientific, USA) and 100 µl chloroform (Sigma Aldrich, Hamburg, Ger-
many), followed by using the RNeasy-HT Kit (Qiagen, Hilden, Germany) as per the manufacturer’s instructions 
on a QiaCube-HT robotic RNA isolation system. Samples were also spiked in with 2.5 µl of 50 nM synthetic 
control microRNA ath-miR-172a (Sigma Aldrich, Hamburg, Germany) during RNA extraction procedure. The 
quantity of total RNA was measured using the NanoDrop spectrophotometer.
OpenArray panels—quantitative real‑time PCR. Complementary (c)DNA was synthesised from total 
RNA using Megaplex RT Primers, Human Pool A and Pool B (ThermoFisher Scientific, USA) and reagents from 
the TaqMan microRNA Reverse Transcription Kit (ThermoFisher Scientific, USA). Each reverse transcription 
(RT) reaction contained a final volume of 7.5 μl (100 ng total RNA input). Pre-amplification was performed 
using Megaplex PreAmp Primers, Human Pool A and B (ThermoFisher Scientific, USA) and TaqMan PreAmp 
Master mix (ThermoFisher Scientific, USA). Pre-amplified product was diluted 1:40 in 0.1X TE buffer (pH 
8.0). Diluted product was then combined with TaqMan OpenArray PCR master mix at a 1:1 ratio and loaded 
onto TaqMan OpenArray Human microRNA Panel (ThermoFisher Scientific, USA) using the AccuFill system. 
RT-qPCR was completed using the QuantStudio 12 K Flex System (Life Technologies, Foster City, CA, USA)38. 
Validation PCR was carried out using the Custom TaqMan OpenArray (ThermoFisher Scientific, USA) accord-
ing to the manufacturer’s ‘low-sample-input’ protocol with custom microRNA RT primer pools, RT spike-in 
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Data analysis. High throughput data generated from TaqMan OpenArray RT-qPCR data were uploaded 
into ThermoFisher Connect for global normalisation and to set a threshold point. MicroRNAs that were unde-
tectable or had an Amp Score < 1.24 and Cq confidence < 0.6 were eliminated, as per the pre-defined QC criteria 
for this study. A cut-off threshold cycle (Ct) value of 39 was defined. Validation panel data were directly imported 
into Excel and normalised using the two spike controls (ath-miR-159a and ath-miR-172a).
Statistical analysis. The relative cycle change (ΔCt =  CtHealthy Control −  CtPatient Sample) between each group was 
calculated using normalised Ct-values and the statistical significance (p value) was calculated by Student t-tests 
in Excel. We used semi-supervised (samples-supervised and microRNA expression-unsupervised) cluster heat-
maps to show the microRNA expression in different toxic agents by grouping the samples as toxic agents with 
the severity of AKI stages (supervised). That allows clustering of microRNAs according to expression in each 
sample. MicroRNAs showing statistically significant changes over ± 4 fold at p < 0.01 were selected and measured 
on the custom OpenArray panel. R statistical program was used to plot heatmaps and t-distributed Stochastic 
Neighbour Embedding (tSNE) plots to visualise differentially expressed microRNAs, through using R pack-
age Heatplus and Rtsne respectively, along with other supportive packages for graphics and resampling. Area 
under the receiver operator characteristics curve (AUC-ROC) analysis was calculated using GraphPad Prism 
8 to evaluate the diagnostic value of candidate microRNAs. Logistic AUC-ROC was calculated to evaluate the 
diagnostic performance of the seven microRNAs using R statistical program (Proc package). Relative abundance 
was calculated from the detectable limit  (2^(39-Ct)). The Jonckheere-Terpstra non-parametric ordered test (with 
ordering of the populations as follows: Healthy controls, NOAKI, AKIN1, AKIN2, AKIN3) was performed to 
identify statistically significant trend between independent groups.
Pathway analysis. We analyzed the expression of the seven microRNAs using co-analysis in Ingenuity 
Pathway Analysis (IPA), (QIAGEN, Inc., https:// targe texpl orer. ingen uity. com/) to find the main disease associa-
tion and functions of these differentially expressed microRNAs. Target mRNAs of these differentially expressed 
microRNAs were examined using microRNA target filter option in IPA (filter criteria: Renal and urological 
disease, all molecular types, Pathways: transport, apoptosis, cellular growth, development and proliferation, cel-
lular stress and injury, ingenuity toxicity list). The target mRNAs were then overlaid on ‘Disease and function’ 
and examined for significant functions and involvement in signalling pathways using Tox function in pathway 
analysis. Finally, the top pathway and the targets were overlayed with the significantly altered microRNAs to plot 
the network diagram.
 Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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